Estimated Effectiveness of Postpartum Maternal Messenger RNA COVID-19 Vaccination Against Delta and Omicron SARS-CoV-2 Infection and Hospitalization in Infants Younger Than 6 Months

Sarah C J Jorgensen; Alejandro Hernandez; Deshayne B Fell; Peter C Austin; Rohan D'Souza; Astrid Guttmann; Jeffrey C Kwong

doi:10.1001/jamapediatrics.2022.6134

Estimated Effectiveness of Postpartum Maternal Messenger RNA COVID-19 Vaccination Against Delta and Omicron SARS-CoV-2 Infection and Hospitalization in Infants Younger Than 6 Months

JAMA Pediatr. 2023 Apr 1;177(4):427-430. doi: 10.1001/jamapediatrics.2022.6134.

Authors

Sarah C J Jorgensen¹, Alejandro Hernandez², Deshayne B Fell³, Peter C Austin², Rohan D'Souza⁴, Astrid Guttmann², Jeffrey C Kwong²

Affiliations

¹ Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
² ICES, Toronto, Ontario, Canada.
³ School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.
⁴ Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada.

No abstract available

Plain language summary

This case-control study estimates the effectiveness of maternal postpartum messenger RNA (mRNA) COVID-19 vaccination against Delta and Omicron SARS-CoV-2 infection and hospitalization in infants younger than 6 months.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 Vaccines
COVID-19* / prevention & control
Female
Hospitalization
Humans
Infant
RNA, Messenger, Stored
SARS-CoV-2 / genetics
Vaccination

Substances

COVID-19 Vaccines
RNA, Messenger, Stored

Grants and funding

CNF 151944/CIHR/Canada